Loading...

FITC anti-mouse CD4 Antibody FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
  • RM4-5
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100509 50 µg NOK248
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100510 500 µg NOK817
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  2. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  3. Wang L, et al. 2018. Exp Ther Med. 15:1532. PubMed
  4. Aimaitijiang A, et al. 2022. Genes Cells. 27:25. PubMed
  5. Yu C, et al. 2022. Invest Ophthalmol Vis Sci. 63:1. PubMed
  6. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  7. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  8. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  9. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  10. Peng Q, et al. 2023. EMBO Rep. 24:e56034. PubMed
  11. Takacs GP, et al. 2023. Front Immunol. 13:993444. PubMed
  12. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  13. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  14. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  15. Chen Y, et al. 2022. Am J Cancer Res. 12:5286. PubMed
  16. Han X, et al. 2022. Nutrients. 14:. PubMed
  17. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  18. Qin T, et al. 2023. Virol J. 20:75. PubMed
  19. Zhang YT, et al. 2023. Front Immunol. 14:1085456. PubMed
  20. Wang X, et al. 2023. NPJ Vaccines. 8:76. PubMed
  21. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  22. Yu HH, et al. 2021. J Am Heart Assoc. 10:e023077. PubMed
  23. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  24. Fachi JL et al. 2019. Cell reports. 27(3):750-761 . PubMed
  25. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  26. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  27. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  28. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  29. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  30. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  31. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  32. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  33. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  34. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  35. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  36. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  37. Li ZX, et al. 2022. Arch Virol. :. PubMed
  38. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  39. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  40. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  41. Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed
  42. Ogawa M, et al. 2019. J Biol Methods. 5:e102. PubMed
  43. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  44. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  45. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  46. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  47. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  48. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  49. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  50. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  51. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  52. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  53. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  54. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  55. Forni MF, et al. 2021. Front Oncol. 11:667715. PubMed
  56. Sundberg T, et al. 2014. Proc Natl Acad Sci U S A. 111:12468. PubMed
  57. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  58. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  59. Graham DB, et al. 2018. Nat Med. 24:1762. PubMed
  60. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  61. Qi X, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.25. PubMed
  62. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  63. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  64. Zhang L, et al. 2021. Methods Mol Biol. 2388:175. PubMed
  65. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  66. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  67. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  68. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  69. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  70. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  71. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  72. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  73. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  74. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  75. Sebastian M, et al. 2016. J Immunol. 196: 144 - 155. PubMed
  76. Wan X, et al. 2018. Nature. 560:107. PubMed
  77. Wheeler MA, et al. 2019. Cell. 176:581. PubMed
  78. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  79. Belgiovine C, et al. 2021. Eur J Immunol. 51:2677. PubMed
  80. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  81. Alhosaini K, et al. 2021. Brain Sci. :11. PubMed
  82. Lischke T, et al. 2013. Infect Immun . 81:4091. PubMed
  83. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  84. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  85. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  86. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  87. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  88. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  89. Lü X, et al. 2021. Exp Ther Med. 22:1005. PubMed
  90. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  91. Aguilera M, et al. 2021. Int J Mol Sci. 22:. PubMed
  92. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  93. Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed
  94. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  95. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  96. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  97. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  98. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  99. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. Sci Rep. 6:39924. PubMed
  100. Kim M, et al. 2018. Immunity. 49:151. PubMed
  101. Papa I, et al. 2017. Nature. 547:318. PubMed
  102. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  103. Zhang J, et al. 2018. Nature. 553:91. PubMed
  104. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  105. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  106. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  107. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  108. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
  109. Uribe-Herranz M, et al. 2018. JCI Insight. 3. PubMed
  110. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  111. Bao Z, et al. 2020. Ann Transplant. 25:e921287. PubMed
  112. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  113. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  114. de Assis LVM, et al. 2022. Commun Biol. 5:461. PubMed
  115. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  116. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  117. Lu J, et al. 2022. Int J Mol Med. 49:. PubMed
  118. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  119. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  120. Baptista M, et al. 2016. Nat Commun. 7:12175. PubMed
  121. Leon-Ponte M, et al. 2006. Blood. 109:3139. PubMed
  122. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  123. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  124. Wang X, et al. 2022. Elife. 11:. PubMed
  125. Helfricht A, et al. 2020. J Exp Med. 217:00:00. PubMed
  126. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  127. Wheeler MA, et al. 2020. Nature. 578:593. PubMed
  128. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  129. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  130. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  131. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  132. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  133. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  134. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  135. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  136. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  137. Siegmund K, et al. 2011. J Immunol. 186:3452. PubMed
  138. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  139. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  140. Wang L, et al. 2018. Exp Ther Med. 15:1532. PubMed
  141. Aimaitijiang A, et al. 2022. Genes Cells. 27:25. PubMed
  142. Yu C, et al. 2022. Invest Ophthalmol Vis Sci. 63:1. PubMed
  143. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  144. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  145. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  146. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  147. Peng Q, et al. 2023. EMBO Rep. 24:e56034. PubMed
  148. Takacs GP, et al. 2023. Front Immunol. 13:993444. PubMed
  149. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  150. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  151. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  152. Chen Y, et al. 2022. Am J Cancer Res. 12:5286. PubMed
  153. Han X, et al. 2022. Nutrients. 14:. PubMed
  154. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  155. Qin T, et al. 2023. Virol J. 20:75. PubMed
  156. Zhang YT, et al. 2023. Front Immunol. 14:1085456. PubMed
  157. Wang X, et al. 2023. NPJ Vaccines. 8:76. PubMed
  158. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  159. Yu HH, et al. 2021. J Am Heart Assoc. 10:e023077. PubMed
  160. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  161. Fachi JL et al. 2019. Cell reports. 27(3):750-761 . PubMed
  162. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  163. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  164. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  165. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  166. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  167. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  168. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  169. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  170. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  171. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  172. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  173. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  174. Li ZX, et al. 2022. Arch Virol. :. PubMed
  175. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  176. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  177. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  178. Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed
  179. Ogawa M, et al. 2019. J Biol Methods. 5:e102. PubMed
  180. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  181. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  182. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  183. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  184. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  185. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  186. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  187. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  188. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  189. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  190. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  191. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  192. Forni MF, et al. 2021. Front Oncol. 11:667715. PubMed
  193. Sundberg T, et al. 2014. Proc Natl Acad Sci U S A. 111:12468. PubMed
  194. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  195. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  196. Graham DB, et al. 2018. Nat Med. 24:1762. PubMed
  197. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  198. Qi X, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.25. PubMed
  199. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  200. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  201. Zhang L, et al. 2021. Methods Mol Biol. 2388:175. PubMed
  202. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  203. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  204. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  205. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  206. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  207. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  208. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  209. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  210. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  211. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  212. Sebastian M, et al. 2016. J Immunol. 196: 144 - 155. PubMed
  213. Wan X, et al. 2018. Nature. 560:107. PubMed
  214. Wheeler MA, et al. 2019. Cell. 176:581. PubMed
  215. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  216. Belgiovine C, et al. 2021. Eur J Immunol. 51:2677. PubMed
  217. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  218. Alhosaini K, et al. 2021. Brain Sci. :11. PubMed
  219. Lischke T, et al. 2013. Infect Immun . 81:4091. PubMed
  220. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  221. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  222. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  223. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  224. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  225. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  226. Lü X, et al. 2021. Exp Ther Med. 22:1005. PubMed
  227. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  228. Aguilera M, et al. 2021. Int J Mol Sci. 22:. PubMed
  229. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  230. Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed
  231. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  232. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  233. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  234. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  235. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  236. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. Sci Rep. 6:39924. PubMed
  237. Kim M, et al. 2018. Immunity. 49:151. PubMed
  238. Papa I, et al. 2017. Nature. 547:318. PubMed
  239. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  240. Zhang J, et al. 2018. Nature. 553:91. PubMed
  241. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  242. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  243. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  244. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  245. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
  246. Uribe-Herranz M, et al. 2018. JCI Insight. 3. PubMed
  247. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  248. Bao Z, et al. 2020. Ann Transplant. 25:e921287. PubMed
  249. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  250. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  251. de Assis LVM, et al. 2022. Commun Biol. 5:461. PubMed
  252. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  253. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  254. Lu J, et al. 2022. Int J Mol Med. 49:. PubMed
  255. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  256. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  257. Baptista M, et al. 2016. Nat Commun. 7:12175. PubMed
  258. Leon-Ponte M, et al. 2006. Blood. 109:3139. PubMed
  259. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  260. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  261. Wang X, et al. 2022. Elife. 11:. PubMed
  262. Helfricht A, et al. 2020. J Exp Med. 217:00:00. PubMed
  263. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  264. Wheeler MA, et al. 2020. Nature. 578:593. PubMed
  265. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  266. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  267. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  268. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  269. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  270. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  271. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  272. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  273. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  274. Siegmund K, et al. 2011. J Immunol. 186:3452. PubMed
RRID
AB_312712 (BioLegend Cat. No. 100509)
AB_312713 (BioLegend Cat. No. 100510)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD4 RM4-5 FC
APC/Cyanine7 anti-mouse CD4 RM4-5 FC
APC/Fire™ 750 anti-mouse CD4 RM4-5 FC
TotalSeq™-A0001 anti-mouse CD4 RM4-5 PG
TotalSeq™-B0001 anti-mouse CD4 RM4-5 PG
TotalSeq™-C0001 anti-mouse CD4 RM4-5 PG
Ultra-LEAF™ Purified anti-mouse CD4 RM4-5 FC,CyTOF®,Depletion,Block,IHC
APC anti-mouse CD4 RM4-5 FC
FITC anti-mouse CD4 RM4-5 FC
PE anti-mouse CD4 RM4-5 FC
Biotin anti-mouse CD4 RM4-5 FC
PE/Cyanine5 anti-mouse CD4 RM4-5 FC
Purified anti-mouse CD4 RM4-5 FC,CyTOF®,IHC-F,IHC
Alexa Fluor® 647 anti-mouse CD4 RM4-5 FC,3D IHC,IHC-F
Alexa Fluor® 488 anti-mouse CD4 RM4-5 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse CD4 RM4-5 FC
Alexa Fluor® 700 anti-mouse CD4 RM4-5 FC
PerCP anti-mouse CD4 RM4-5 FC
PerCP/Cyanine5.5 anti-mouse CD4 RM4-5 FC
Brilliant Violet 421™ anti-mouse CD4 RM4-5 FC,ICC,IHC-F
Brilliant Violet 570™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 605™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 650™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 711™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 785™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 510™ anti-mouse CD4 RM4-5 FC
Purified anti-mouse CD4 (Maxpar® Ready) RM4-5 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD4 RM4-5 FC
Spark Violet™ 423 anti-mouse CD4 RM4-5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) RM4-5 FC
APC/Fire™ 810 anti-mouse CD4 RM4-5 FC
PE/Fire™ 640 anti-mouse CD4 Antibody RM4-5 FC
Brilliant Violet 750™ anti-mouse CD4 Antibody RM4-5 FC
StarBright UltraViolet 740 anti-mouse CD4 RM4-5 FC
Spark YG™ 581 anti-mouse CD4 (Flexi-Fluor™) RM4-5 FC
Go To Top Version: 3    Revision Date: 01.29.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
  • RM4-5
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100509 50 µg NOK248
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100510 500 µg NOK817
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  2. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  3. Wang L, et al. 2018. Exp Ther Med. 15:1532. PubMed
  4. Aimaitijiang A, et al. 2022. Genes Cells. 27:25. PubMed
  5. Yu C, et al. 2022. Invest Ophthalmol Vis Sci. 63:1. PubMed
  6. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  7. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  8. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  9. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  10. Peng Q, et al. 2023. EMBO Rep. 24:e56034. PubMed
  11. Takacs GP, et al. 2023. Front Immunol. 13:993444. PubMed
  12. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  13. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  14. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  15. Chen Y, et al. 2022. Am J Cancer Res. 12:5286. PubMed
  16. Han X, et al. 2022. Nutrients. 14:. PubMed
  17. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  18. Qin T, et al. 2023. Virol J. 20:75. PubMed
  19. Zhang YT, et al. 2023. Front Immunol. 14:1085456. PubMed
  20. Wang X, et al. 2023. NPJ Vaccines. 8:76. PubMed
  21. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  22. Yu HH, et al. 2021. J Am Heart Assoc. 10:e023077. PubMed
  23. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  24. Fachi JL et al. 2019. Cell reports. 27(3):750-761 . PubMed
  25. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  26. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  27. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  28. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  29. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  30. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  31. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  32. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  33. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  34. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  35. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  36. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  37. Li ZX, et al. 2022. Arch Virol. :. PubMed
  38. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  39. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  40. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  41. Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed
  42. Ogawa M, et al. 2019. J Biol Methods. 5:e102. PubMed
  43. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  44. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  45. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  46. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  47. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  48. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  49. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  50. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  51. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  52. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  53. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  54. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  55. Forni MF, et al. 2021. Front Oncol. 11:667715. PubMed
  56. Sundberg T, et al. 2014. Proc Natl Acad Sci U S A. 111:12468. PubMed
  57. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  58. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  59. Graham DB, et al. 2018. Nat Med. 24:1762. PubMed
  60. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  61. Qi X, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.25. PubMed
  62. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  63. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  64. Zhang L, et al. 2021. Methods Mol Biol. 2388:175. PubMed
  65. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  66. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  67. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  68. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  69. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  70. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  71. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  72. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  73. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  74. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  75. Sebastian M, et al. 2016. J Immunol. 196: 144 - 155. PubMed
  76. Wan X, et al. 2018. Nature. 560:107. PubMed
  77. Wheeler MA, et al. 2019. Cell. 176:581. PubMed
  78. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  79. Belgiovine C, et al. 2021. Eur J Immunol. 51:2677. PubMed
  80. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  81. Alhosaini K, et al. 2021. Brain Sci. :11. PubMed
  82. Lischke T, et al. 2013. Infect Immun . 81:4091. PubMed
  83. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  84. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  85. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  86. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  87. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  88. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  89. Lü X, et al. 2021. Exp Ther Med. 22:1005. PubMed
  90. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  91. Aguilera M, et al. 2021. Int J Mol Sci. 22:. PubMed
  92. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  93. Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed
  94. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  95. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  96. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  97. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  98. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  99. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. Sci Rep. 6:39924. PubMed
  100. Kim M, et al. 2018. Immunity. 49:151. PubMed
  101. Papa I, et al. 2017. Nature. 547:318. PubMed
  102. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  103. Zhang J, et al. 2018. Nature. 553:91. PubMed
  104. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  105. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  106. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  107. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  108. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
  109. Uribe-Herranz M, et al. 2018. JCI Insight. 3. PubMed
  110. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  111. Bao Z, et al. 2020. Ann Transplant. 25:e921287. PubMed
  112. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  113. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  114. de Assis LVM, et al. 2022. Commun Biol. 5:461. PubMed
  115. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  116. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  117. Lu J, et al. 2022. Int J Mol Med. 49:. PubMed
  118. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  119. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  120. Baptista M, et al. 2016. Nat Commun. 7:12175. PubMed
  121. Leon-Ponte M, et al. 2006. Blood. 109:3139. PubMed
  122. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  123. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  124. Wang X, et al. 2022. Elife. 11:. PubMed
  125. Helfricht A, et al. 2020. J Exp Med. 217:00:00. PubMed
  126. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  127. Wheeler MA, et al. 2020. Nature. 578:593. PubMed
  128. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  129. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  130. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  131. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  132. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  133. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  134. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  135. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  136. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  137. Siegmund K, et al. 2011. J Immunol. 186:3452. PubMed
  138. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  139. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  140. Wang L, et al. 2018. Exp Ther Med. 15:1532. PubMed
  141. Aimaitijiang A, et al. 2022. Genes Cells. 27:25. PubMed
  142. Yu C, et al. 2022. Invest Ophthalmol Vis Sci. 63:1. PubMed
  143. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  144. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  145. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  146. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  147. Peng Q, et al. 2023. EMBO Rep. 24:e56034. PubMed
  148. Takacs GP, et al. 2023. Front Immunol. 13:993444. PubMed
  149. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  150. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  151. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  152. Chen Y, et al. 2022. Am J Cancer Res. 12:5286. PubMed
  153. Han X, et al. 2022. Nutrients. 14:. PubMed
  154. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  155. Qin T, et al. 2023. Virol J. 20:75. PubMed
  156. Zhang YT, et al. 2023. Front Immunol. 14:1085456. PubMed
  157. Wang X, et al. 2023. NPJ Vaccines. 8:76. PubMed
  158. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  159. Yu HH, et al. 2021. J Am Heart Assoc. 10:e023077. PubMed
  160. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  161. Fachi JL et al. 2019. Cell reports. 27(3):750-761 . PubMed
  162. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  163. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  164. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  165. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  166. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  167. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  168. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  169. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  170. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  171. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  172. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  173. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  174. Li ZX, et al. 2022. Arch Virol. :. PubMed
  175. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  176. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  177. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  178. Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed
  179. Ogawa M, et al. 2019. J Biol Methods. 5:e102. PubMed
  180. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  181. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  182. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  183. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  184. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  185. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  186. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  187. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  188. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  189. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  190. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  191. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  192. Forni MF, et al. 2021. Front Oncol. 11:667715. PubMed
  193. Sundberg T, et al. 2014. Proc Natl Acad Sci U S A. 111:12468. PubMed
  194. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  195. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  196. Graham DB, et al. 2018. Nat Med. 24:1762. PubMed
  197. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  198. Qi X, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.25. PubMed
  199. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  200. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  201. Zhang L, et al. 2021. Methods Mol Biol. 2388:175. PubMed
  202. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  203. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  204. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  205. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  206. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  207. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  208. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  209. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  210. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  211. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  212. Sebastian M, et al. 2016. J Immunol. 196: 144 - 155. PubMed
  213. Wan X, et al. 2018. Nature. 560:107. PubMed
  214. Wheeler MA, et al. 2019. Cell. 176:581. PubMed
  215. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  216. Belgiovine C, et al. 2021. Eur J Immunol. 51:2677. PubMed
  217. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  218. Alhosaini K, et al. 2021. Brain Sci. :11. PubMed
  219. Lischke T, et al. 2013. Infect Immun . 81:4091. PubMed
  220. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  221. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  222. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  223. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  224. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  225. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  226. Lü X, et al. 2021. Exp Ther Med. 22:1005. PubMed
  227. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  228. Aguilera M, et al. 2021. Int J Mol Sci. 22:. PubMed
  229. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  230. Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed
  231. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  232. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  233. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  234. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  235. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  236. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. Sci Rep. 6:39924. PubMed
  237. Kim M, et al. 2018. Immunity. 49:151. PubMed
  238. Papa I, et al. 2017. Nature. 547:318. PubMed
  239. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  240. Zhang J, et al. 2018. Nature. 553:91. PubMed
  241. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  242. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  243. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  244. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  245. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
  246. Uribe-Herranz M, et al. 2018. JCI Insight. 3. PubMed
  247. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  248. Bao Z, et al. 2020. Ann Transplant. 25:e921287. PubMed
  249. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  250. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  251. de Assis LVM, et al. 2022. Commun Biol. 5:461. PubMed
  252. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  253. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  254. Lu J, et al. 2022. Int J Mol Med. 49:. PubMed
  255. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  256. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  257. Baptista M, et al. 2016. Nat Commun. 7:12175. PubMed
  258. Leon-Ponte M, et al. 2006. Blood. 109:3139. PubMed
  259. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  260. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  261. Wang X, et al. 2022. Elife. 11:. PubMed
  262. Helfricht A, et al. 2020. J Exp Med. 217:00:00. PubMed
  263. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  264. Wheeler MA, et al. 2020. Nature. 578:593. PubMed
  265. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  266. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  267. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  268. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  269. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  270. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  271. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  272. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  273. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  274. Siegmund K, et al. 2011. J Immunol. 186:3452. PubMed
RRID
AB_312712 (BioLegend Cat. No. 100509)
AB_312713 (BioLegend Cat. No. 100510)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD4 RM4-5 FC
APC/Cyanine7 anti-mouse CD4 RM4-5 FC
APC/Fire™ 750 anti-mouse CD4 RM4-5 FC
TotalSeq™-A0001 anti-mouse CD4 RM4-5 PG
TotalSeq™-B0001 anti-mouse CD4 RM4-5 PG
TotalSeq™-C0001 anti-mouse CD4 RM4-5 PG
Ultra-LEAF™ Purified anti-mouse CD4 RM4-5 FC,CyTOF®,Depletion,Block,IHC
APC anti-mouse CD4 RM4-5 FC
FITC anti-mouse CD4 RM4-5 FC
PE anti-mouse CD4 RM4-5 FC
Biotin anti-mouse CD4 RM4-5 FC
PE/Cyanine5 anti-mouse CD4 RM4-5 FC
Purified anti-mouse CD4 RM4-5 FC,CyTOF®,IHC-F,IHC
Alexa Fluor® 647 anti-mouse CD4 RM4-5 FC,3D IHC,IHC-F
Alexa Fluor® 488 anti-mouse CD4 RM4-5 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse CD4 RM4-5 FC
Alexa Fluor® 700 anti-mouse CD4 RM4-5 FC
PerCP anti-mouse CD4 RM4-5 FC
PerCP/Cyanine5.5 anti-mouse CD4 RM4-5 FC
Brilliant Violet 421™ anti-mouse CD4 RM4-5 FC,ICC,IHC-F
Brilliant Violet 570™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 605™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 650™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 711™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 785™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 510™ anti-mouse CD4 RM4-5 FC
Purified anti-mouse CD4 (Maxpar® Ready) RM4-5 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD4 RM4-5 FC
Spark Violet™ 423 anti-mouse CD4 RM4-5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) RM4-5 FC
APC/Fire™ 810 anti-mouse CD4 RM4-5 FC
PE/Fire™ 640 anti-mouse CD4 Antibody RM4-5 FC
Brilliant Violet 750™ anti-mouse CD4 Antibody RM4-5 FC
StarBright UltraViolet 740 anti-mouse CD4 RM4-5 FC
Spark YG™ 581 anti-mouse CD4 (Flexi-Fluor™) RM4-5 FC
Go To Top Version: 3    Revision Date: 01.29.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account